Triaryl methane compounds and analogues thereof useful for the t

Details Triaryl methane compounds and analogues thereof useful for the t Triaryl methane compounds and analogues thereof useful for the t

1997-03-19

2000-02-22

Richter, Johann

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heavy metal containing doai

558401, 558405, 558407, 514319, 514358, 514410, 514183, 552101, 552100, 552105, 556489, 560312, 564316, A61K 3128, C07C25504

Patent

active

060281030

ABSTRACT:
The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

REFERENCES:
patent: 4006023 (1977-02-01), McLaughlin et al.
patent: 4551526 (1985-11-01), Mai et al.
patent: 4806685 (1989-02-01), Abraham et al.
patent: 5273992 (1993-12-01), Brugnara et al.
patent: 5358959 (1994-10-01), Halperin et al.
patent: 5430062 (1995-07-01), Cushman et al.
Aldrich Catalog, 1994-1995, Compounds 13,484-8; T8,380-1; 10,130-3; D21,320-9; 32,543-0; 35,890-8; T8,160-4; 25,657-9; T8,470-0; T8,417-7; T8,360-7; S36,533-5; S50,949-3; 37,411-3; 37,152-1; 30,151-5; 27,520-4; 34,182-7; 35,889-4; S84,240-0; S79,226-8; 27,519-0; S64,640-7; S81,477-6; 36,005-8; S70,627-2; S34,966-6; S87,739-5; 11,500-2;S 83,881-0; S58,110-0; 21,560-0; S91,408-8; S60,147-0; S83,571-4; S82,654-5; S8,388-2; S94,371-1; S87,649-6; S83,719-9; S83,042-9; S82,162-4; S81,468-7; S82,290-6; S79,387.
Ando and Ikeno, 1979, Tetrahedron Lett. 51:4941-4942.
Bartroli et al., 1992, Arzneim-Forsch./Drug Res. 42:832-835.
Benjamin et al., 1986, Blood 67:1442-1447.
Benzaquen et al., 1995, Nature Medicine 1:534-540.
Berkowitz and Orringer, 1984, Am. J. Hematol. 17:217-223.
Beutler and West, 1976, J. Lab. Clin. Med. 88:328-333.
Bontems et al., 1992, Biochemistry 31:7756-7764.
Brugnara, 1995, Advanced Course and International Symposium on Membrane Transports and Channels: Program and Abstracts Lecture 34.
Brugnara et al., 1993, J. Clin. Invest. 92:520-526.
Brugnara et al., 1993, J. Biol. Chem. 268(12):8760-8768.
Brugnara et al., 1994, Blood (220a):865.
Brugnara et al., 1995, JPET 273:266-272.
Brugnara et al., 1995, The 20th Annual Meeting of the National Sickle Cell Program, p. 138.
Brugnara et al., 1996, J. Clin. Invest. 97(5):1227-1234.
Burgess and Bodey, 1972, Antimicrobial Agents and Chemotherapy 2(6):423-426.
Byers et al., 1993, Melanoma Res. 3:247-253.
Carter et al., 1994, J. Am. Coll. Cardiol. 24(5):1398-1405.
Charache and Walker, 1981, Blood 58:892-896.
Charache et al., 1995, N. Engl. J. Med. 332(20):1317-1322.
Chemical Abstracts , 1993, 119:92, col. 2, abstract No. 63033j.
Clark et al., 1982, J. Clin. Invest. 70;1074-1080.
Conte et al., 1992, Arzheim-Forsch./Drug Res. 42:847-853.
Conte et al., 1992, Arzheim-Forsch./Drug Res. 42:854-858.
Corbett et al., 1996, J. Exp. Ther. Oncol. 1: 95-108.
De Franceschi et al., 1994, J. Clin. Invest. 93: 1670-1676.
De Franceschi et al., 1996, Blood 88(648a):2580.
Douchene et al., 1992, Arzheim-Forsch./Drug Res. 42:861-863.
Duhm et al., 1974, Postgraduate Medical Journal Jul. Suppl. :13-16.
Dykes et al., 1992, Contrib. Oncol. Basel. Karger 42:1-22.
Eaton and Hofrichter, 1987, Blood 70:1245-1266.
Epstein et al., 1987, Cornea 6(4):250-257.
Ethridge et al., 1990, J. Production Agriculture 3(2):246-252.
Fahim and Pressman, 1981, Life Sciences 29:1959-1966.
Fan et al., 1983, Yiyao Gongye 9:2-4.
Ferguson et al., 1992, Acta Crystallogr. C48:1228-1231.
Fingl and Woodbury, 1975, In: The Pharmacological Basis of Therapeutics , Ch. 1 p1.
Fleming et al., 1982, Tetrahedron Letters 23:2053-2056.
Gait, 1984, Oligonucleotide Synthesis: A Pratical Approach , IRL Press, Oxford, pp. 13 and 76.
Glidewell and Ferguson, 1994, Acta Crystallogr. C50:1362-1366.
Goldberg et al., 1990, N. Engl. J. Med. 323(6):366-372.
Grinstein and Smith, 1990, J. Gen. Physiol. 95:97-120.
Guy et al., 1973, Am. J. Med. Sci. 266:267-277.
Illes et al., 1988, Acta Phytopathologica et Entomologia Hungarica 23:243-255.
Hoch and Lecocq, 1957, Academie des Sciences 245:73-75.
Holt and Newman, 1972, J. Clin. Path. 25:1089-1097.
Hoogerheide and Wyka, 1982, Analytical Profiles of Drug Substances 11:225-255.
Illes et al., 1988, Acta Phytopathologica et Entomologia Hungarcia 23:243-255.
Izquierdo et al., 1992, Arzheim-Forsch./Drug Res. 42:859-860.
Lewis et al., 1980, J. Am. Chem. Soc. 102:4659-4664.
Li, F. et al., 1996, Metal-Based Drugs 3:241-242.
Liu & Paike, 1987, Tetrahedron Lett. 28(33):3763-3766.
Matsuura et al., 1991, Biochemical Pharmacology 41:1949-1956.
Miller et al., 1985, Nature 313:316-318.
Montero et al., 1991, Biochem. J. 277-73-79.
O'Donnell, M. et al., 1995, Boorganic & Medicinal Chemistry 3:743-750.
Owens et al., 1984, Arch Intern Med 144:290-293.
Paike, 1992, Mater. Sci. 18:53-57.
Paoletti, E. G. et al., 1969, Advan. Exp. Med. Biol. 22:457-471.
Paoletti, E. G. et al., 1971, J. Neurosurg 34:454-455.
Paoletti, P et al., 1972, In: The Exp. Biol. Of Brain Tumors, 457-479.
Pappas and Franklin, 1993, Toxicology 80:27-35.
Park et al., 1991, Proc. Natl. Acad. Sci. U.S.A. 88:2046-2050.
Peppelenbosch et al., 1991, J. Biol. Chem. 266:19938-19944.
Perrine et al., 1993, N. Engl. J. Med. 328(2):81-86.
Petersen, P. M. et al., 1996, Bioorganic and Medicinal Chemistry 4:1107-1112.
Ponnuswamy and Trotter, 1984, Acta Crystallogr. C40:142-144.
Rafanell et al., 1992, Arzheim-Forsch./Drug Res. 42:836-840.
Rideout, D. C. et al., 1989, Anti-Cancer Drug Design 4:265-280.
Rideout, D. et al., 1994, Int. J. Cancer 57:247-253.
Ritter, 1985, Am. J. Obstet. Gynecol. 152:945-947.
Ritter et al., 1982, Chemotherapy 28(Suppl. 1):37-42.
Rosa et al., 1980, M. Eng. J. Med. 303:1138-1143.
Rubright, W. C. et al., 1967, Cancer Research 27:165-171.
Sawyer et al., 1975, Drugs 9:424-447.
Simig, G. et al., 1978, Tetrahedron 34:2371-2375.
Stuart et al., 1987, J. Clin. Pathol. 40:1182-1186.
Stuart et al., 1994, British J. Haematol. 86:820-823.
Tomioka et al., 1981, Chem. Lett. 11:1621-1624.
Trudel et al., 1991, EMBO J. 11:3157-3165.
Vazquez et al., 1989, J. Biol. Chem. 264:20902-20909.
Vericat et al., 1992, Arzheim-Forsch./Drug Res. 42:841-846.
Villalobos et al., 1992, FASEB J. 6:2742-2747.
Weuta, 1974, Postgraduate Medical Journal (Jul. Suppl.):45-48.
Wyche, J. H. and William D. Noteboom, 1979, Endocrinology 104:1765-1773.
Zhu et al., 1994, Cardiology 85:370-377.

Affiliated with

Also associated with

Rating

Triaryl methane compounds and analogues thereof useful for the t does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triaryl methane compounds and analogues thereof useful for the t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triaryl methane compounds and analogues thereof useful for the t will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-520927